跳转至内容
Merck
CN

R9644

Sigma-Aldrich

利巴韦林

antiviral

登录查看公司和协议定价

别名:
1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺
经验公式(希尔记法):
C8H12N4O5
CAS号:
分子量:
244.20
MDL编号:
UNSPSC代码:
12352202
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (TLC)

形式

powder

溶解性

water: 19.60-20.40 mg/mL, clear, colorless to faintly yellow

抗生素抗菌谱

viruses

作用机制

DNA synthesis | interferes

储存温度

2-8°C

SMILES字符串

NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1

InChI key

IWUCXVSUMQZMFG-AFCXAGJDSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

化学结构:核苷
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。

生化/生理作用

用于抵御多种人类病毒感染的抗病毒剂,特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸,是肌苷一磷酸 (IMP) 脱氢酶的抑制剂,但也有实验证据支持许多其他作用机制。
抗病毒剂。其代谢产物利巴韦林 5′-磷酸,是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。用于抑制嘌呤(GTP 池)在肌苷单磷酸 (IMP) 脱氢酶级别的生物合成,并作为抑制病毒RNA依赖性RNA聚合酶的二磷酸和三磷酸的前体。

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Muta. 2 - Repr. 1B

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Colombo et al.
Gut, 63(7), 1150-1158 (2013-11-10)
Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and
Tao Meng et al.
Journal of virology, 88(10), 5803-5815 (2014-03-14)
In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp
Marie Pellerin et al.
Viruses, 13(3) (2021-04-04)
Hepatitis E virus (HEV) is considered as an emerging global health problem. In most cases, hepatitis E is a self-limiting disease and the virus is cleared spontaneously without the need of antiviral therapy. However, immunocompromised individuals can develop chronic infection
Chen-Hua Liu et al.
Annals of internal medicine, 159(11), 729-738 (2013-12-04)
Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and
Fred Poordad et al.
The New England journal of medicine, 370(21), 1973-1982 (2014-04-15)
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门